Ionis Pharmaceuticals
IONS
44.16
+0.16
+0.36%
Ionis Pharmaceuticals
US · IONS
#1749 by market cap
Listed 1970
44.16
+0.16
+0.36%
Live - 5344 symbols - heartbeat 479s ago
· 2026-10-08 07:13
Pre-market
44.41
+0.57%
After-hours
44.16
0.00%
- Market cap
- 7.34B
- P/E (TTM)i
- -12.69
- P/Bi
- 16.69
- EPSi
- -2.38
- Div yieldi
- 0.00%
- 52W posi
- 3%
Reader sentiment
Are you bullish or bearish on IONS?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.3 percentage points.
Institutional ownership
- Held by institutions
- 109.71% -0.32pp
- Institutions
- 617 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund87.92%
Hedge Fund11.75%
Public Company5.25%
VC/PE Fund1.80%
Government Pension Fund1.29%
Private Company1.24%
Individual/Insider0.78%
Insurance Company0.21%
Top holders as of 2026-06-30
FMR
14.82% · 24.63M sh
Capital Research
13.73% · 22.82M sh
BlackRock
6.44% · 10.70M sh
Vanguard Capital Management, LLC
4.98% · 8.27M sh
Vanguard Portfolio Management, LLC
4.73% · 7.86M sh
Wellington Management Group
4.60% · 7.65M sh
T. Rowe Price Group, Inc.
4.30% · 7.14M sh
Two Sigma Investments, LP
3.76% · 6.25M sh
State Street Global Advisors
2.61% · 4.33M sh
Geode Capital Management, LLC
2.16% · 3.58M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Brett Monia | Chief Executive Officer | 0.15% |
| Spencer Berthelsen | Independent Director | 0.10% |
| Brian Birchler | Executive Vice President of Corporate & Development Operations | 0.06% |
| Elizabeth Hougen | Chief Financial Officer | 0.05% |
| Michael Hayden | Independent Director | 0.05% |
| Eugene Schneider | Executive VP & Chief Clinical Development Officer | 0.05% |
| C. Bennett | Chief Scientific Officer | 0.05% |
| Richard Geary | Chief Development Officer | 0.04% |
| Patrick O'Neil | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | 0.04% |
| Joseph Baroldi | Executive VP & Chief Business Officer | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-30 | C. Bennett | Chief Scientific Officer | Other Acquisition | +110 | $51.31 |
| 2026-08-30 | Brett Monia | Chief Executive Officer | Other Acquisition | +98 | $51.31 |
| 2026-08-30 | Patrick O'Neil | Executive VP, Chief Legal Officer, General Counsel & Corporate Secretary | Other Acquisition | +63 | $51.31 |
| 2026-08-30 | Brian Birchler | Executive Vice President of Corporate & Development Operations | Other Acquisition | +58 | $51.31 |
| 2026-07-30 | Michael Hayden | Independent Director | Open Market Acquisition | +20,000 | $51.60–53.38 |
| 2026-07-14 | Joan Herman | Independent Director | Derivative Exercise and Retained | +5,220 | -- |
| 2026-07-14 | Spencer Berthelsen | Independent Director | Derivative Exercise and Retained | +5,220 | -- |
| 2026-07-14 | Ludwig Hantson | Director | Other Derivative Acquisition | +3,399 | -- |
| 2026-07-14 | Peter Reikes | Former Independent Director | Other Derivative Acquisition | +3,399 | -- |
| 2026-07-06 | C. Bennett | Chief Scientific Officer | Other Acquisition | +15,000 | -- |
| 2026-07-06 | C. Bennett | Chief Scientific Officer | Automatic Disposition | -20,536 | $83.58–85.46 |
| 2026-07-06 | C. Bennett | Chief Scientific Officer | Other Derivative Disposition | -15,000 | -- |
| 2026-07-06 | Allene Diaz | Independent Director | Derivative Exercise and Sale | -10,111 | $47.11–85.42 |
| 2026-07-06 | Holly Kordasiewicz | Senior Vice President of Neurology | Automatic Disposition | -362 | $84.30 |
| 2026-06-30 | Joan Herman | Independent Director | Other Derivative Acquisition | +2,301 | -- |
| 2026-06-30 | Joan Herman | Independent Director | Other Derivative Acquisition | +5,369 | $79.19 |
| 2026-06-30 | Joseph Klein | Independent Director | Derivative Exercise and Sale | -11,518 | $39.94–79.45 |
| 2026-06-30 | Joseph Klein | Independent Director | Other Derivative Acquisition | +2,301 | -- |
| 2026-06-30 | Joseph Klein | Independent Director | Other Derivative Acquisition | +5,369 | $79.19 |
| 2026-06-30 | Michael Hayden | Independent Director | Other Derivative Acquisition | +2,301 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:13:52 · For reference only, not investment advice and not tailored to your situation.